TXMD — TherapeuticsMD Income Statement
0.000.00%
Last trade - 00:00
- $22.95m
- $18.62m
- $1.30m
- 14
- 32
- 38
- 18
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 49.6 | 64.9 | 2.57 | 70 | 1.3 |
Cost of Revenue | |||||
Gross Profit | 43.3 | 48.9 | 1.17 | 68.6 | 1.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 211 | 220 | 82.2 | 68.8 | 9.82 |
Operating Profit | -161 | -156 | -79.6 | 1.19 | -8.52 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -176 | -184 | -79.3 | 1.07 | -7.74 |
Provision for Income Taxes | |||||
Net Income After Taxes | -176 | -184 | -79.3 | 1.07 | -7.7 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -176 | -184 | -172 | 112 | -10.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -176 | -184 | -172 | 112 | -10.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -33.7 | -33.1 | -9.96 | 1.13 | -0.737 |